Use of an irak4 modulator for gene therapy
AssigneeGenzyme Corporation
InventorsSourav Roy CHOUDHURY, Mona MOTWANI, Christian MUELLER, John REED
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK degrader with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK degrader in combination with a gene therapy agent.
Claims98
A method for delivering nucleic acid to a cell of an individual in need thereof, the method comprising
- a) administering an IRAK degrader to the individual, and
- b) administering a gene therapy agent to the individual.
A method for treating an individual in need thereof with a gene therapy agent, the method comprising
- a) administering an IRAK degrader to the individual, and
- b) administering the gene therapy agent to the individual.
A method for improving gene therapy in an individual in need thereof, the method comprising
- a) administering an IRAK degrader to the individual, and
- b) administering a gene therapy agent to the individual.
A method for suppressing an immune response to a gene therapy agent in an individual in need thereof, the method comprising
- a) administering an IRAK degrader to the individual, and
- b) administering a gene therapy agent to the individual.
A method for delivering a nucleic acid to a cell of an individual in an individual in need thereof, the method comprising
- a) incubating innate immune cells from the individual with the gene therapy agent,
- b) analyzing the innate immune cells for the expression of one or more cytokines wherein expression of a cytokine signature following incubation with the gene therapy agent identifies an individual with innate immunity to the gene therapy agent,
- c) administering an IRAK degrader to the individual identified in step b), and
- d) administering the gene therapy agent to the individual identified in step b).
A method for treating an individual in need thereof, the method comprising
- a) incubating innate immune cells from the individual with the gene therapy agent,
- b) analyzing the innate immune cells for the expression of one or more cytokines wherein expression of a cytokine signature following incubation with the gene therapy agent identifies an individual with innate immunity to the gene therapy agent,
- c) administering an IRAK degrader to the individual identified in step b), and
- d) administering the gene therapy agent to the individual identified in step b).
A method for selecting an individual for treatment with a gene therapy agent and an IRAK degrader, the method comprising
- a) incubating innate immune cells from the individual with the gene therapy agent,
- b) analyzing the innate immune cells for the expression of one or more cytokines wherein expression of a cytokine signature following incubation with the gene therapy agent identifies an individual for treatment with a gene therapy agent and an IRAK degrader.
- c) selecting the individual identified in step b) for treatment with a gene therapy agent and an IRAK degrader.
Use of a composition in the manufacture of a medicament for delivering nucleic acid to a cell of an individual in need thereof, wherein the composition comprises a gene therapy agent, and wherein the composition is formulated for use in combination with an IRAK degrader.
Use of a composition in the manufacture of a medicament for delivering nucleic acid to a cell of an individual in need thereof, wherein the composition comprises an IRAK degrader, and wherein the composition is formulated for use in combination with a gene therapy agent.
Use of a composition in the manufacture of a medicament for treating an individual in need of gene therapy, wherein the composition comprises a gene therapy agent, and wherein the composition is formulated for use in combination with an IRAK degrader.
Use of a composition in the manufacture of a medicament for treating an individual in need of gene therapy, wherein the composition comprises an IRAK degrader, and wherein the composition is formulated for use in combination with a gene therapy agent.
Use of a composition in the manufacture of a medicament for modulating an immune response to gene therapy in an individual in need of gene therapy, wherein the composition comprises a gene therapy agent, and wherein the composition is formulated for use in combination with an IRAK degrader.
Use of a composition in the manufacture of a medicament for modulating an immune response to gene therapy in an individual, wherein the composition comprises an IRAK degrader, and wherein the composition is formulated for use in combination with a gene therapy agent.
A composition comprising a gene therapy agent for use in delivering nucleic acid to a cell of an individual in need thereof, wherein the gene therapy agent is used in combination with an IRAK degrader.
A composition comprising an IRAK degrader for use in delivering nucleic acid to a cell of an individual in need thereof, wherein the IRAK degrader is used in combination with a gene therapy agent.
A composition comprising a gene therapy agent for use in treating an individual in need of gene therapy, wherein the gene therapy agent is used in combination with an IRAK degrader.
A composition comprising an IRAK degrader for use in treating an individual in need of gene therapy, wherein the IRAK degrader is used in combination with a gene therapy agent.
A composition comprising an IRAK degrader for modulating an immune response to gene therapy in an individual in need of gene therapy, wherein the IRAK degrader is used in combination with a gene therapy agent.
A composition comprising an IRAK degrader for suppressing an immune response to gene therapy in an individual in need of gene therapy, wherein the IRAK degrader is used in combination with a gene therapy agent.
Dependencies are inferred from the claim text.